Emerging therapies in osteoporosis
- 31 July 2001
- journal article
- review article
- Published by Elsevier BV in Best Practice & Research Clinical Rheumatology
- Vol. 15 (3), 483-496
- https://doi.org/10.1053/berh.2001.0162
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Who Has Osteoporosis? A Conflict Between Clinical and Public Health PerspectivesJournal of Bone and Mineral Research, 2000
- The selective oestrogen receptor modulators idoxifene and raloxifene have fundamentally different cell-specific oestrogen-response element (ERE)-dependent/independent mechanisms in vitroEuropean Journal Of Cancer, 2000
- Therapeutic equivalence of alendronate 70 mg onceweekly and alendronate 10 mg daily in the treatment of osteoporosisAging Clinical and Experimental Research, 2000
- Antifracture Efficacy of Antiresorptive Agents Are Related to Changes in Bone DensityJournal of Clinical Endocrinology & Metabolism, 2000
- Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal OsteoporosisA Randomized Controlled TrialJAMA, 1999
- Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With RaloxifeneResults From a 3-Year Randomized Clinical TrialJAMA, 1999
- Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral FracturesResults From the Fracture Intervention TrialJAMA, 1998
- Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracturesThe Lancet, 1996
- Antibody to beta3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat.Endocrinology, 1996
- A model for estimating the potential costs and savings of osteoporosis prevention strategiesBone, 1988